At a glance
| Field | Details |
|---|---|
| Brand names | Not yet approved |
| Targets | GLP-1R + GIPR |
| Developer | Viking Therapeutics |
| Modality | SC injection weekly / oral tablet daily (separate formulations) |
| Approval status | Phase 3 |
| Key efficacy | 14.7% at 13 weeks (sub-Q Phase 2); ~8.2% at 13 weeks (oral Phase 2) |
| Indications | Obesity, T2D |
User Sentiment
VK2735 is still in clinical trials, so patient community data is from trial participants and early research followers rather than a broad prescriber base. Interest is high specifically around the oral formulation — people who want GLP-1 drug benefits without injections are watching Phase 3 closely.
Example(What trial participants report)
Phase 2 VENTURE participants reported weight loss and appetite reduction consistent with the tirzepatide class, with a tolerability profile similar to injectable GLP-1/GIP drugs. The oral Phase 2 cohort noted the convenience difference vs Rybelsus specifically — no fasting requirement, no timing restrictions.
How it works
GLP-1/GIP dual agonist with the same mechanistic framework as tirzepatide — simultaneous GLP-1R and GIPR activation from a single peptide. The strategic differentiation is in delivery: Viking is developing both an injectable and a separate oral small-molecule formulation. If the oral dual agonist holds up in Phase 3, VK2735 would be the first drug combining dual receptor efficacy with oral convenience.
Intuition(Why an oral dual agonist is structurally different from oral semaglutide)
Oral semaglutide (Rybelsus) requires an absorption enhancer, strict fasting, and achieves lower systemic exposure than injectable semaglutide — all because peptides are degraded in the gut. VK2735's oral formulation is a small molecule (not a peptide), so it doesn't need any of those workarounds. It survives gut transit, absorbs through conventional mechanisms, and has no food or timing restrictions. If Phase 3 confirms dual-agonist efficacy (~19–21% range) in a once-daily pill with no restrictions, the market comparison is to Rybelsus — not to injectable drugs.
Trial data
VENTURE (sub-Q Phase 2, 13 weeks): 14.7% weight loss. Short duration makes direct comparison to tirzepatide's 72-week numbers difficult, but the trajectory suggests competitive efficacy at full trial length.
ACHIEVE-1 (oral Phase 2, 13 weeks): ~8.2% weight loss — strong for an oral agent at this timepoint, better than oral semaglutide (Rybelsus) at comparable duration, and meaningful as a dual-agonist oral candidate.
What to Expect
Sub-Q formulation (once-weekly): Based on Phase 2 trajectory, expect a tirzepatide-like arc — GI side effects during escalation, food noise reduction by month 2, meaningful weight loss by month 3–4.
Oral formulation (once-daily): Phase 2 showed ~8.2% at 13 weeks — early, but strong for an oral agent. No food restrictions. Tolerability data pending at longer duration in Phase 3.
Not yet available for prescription — Phase 3 data expected before 2027 filing.
Dosing and administration
Sub-Q: once-weekly injection. Oral: once-daily tablet. Phase 3 titration schedules [verify final protocols].
Development status
| Milestone | Status |
|---|---|
| Sub-Q Phase 2 | Complete — 14.7% at 13 weeks |
| Oral Phase 2 | Complete — 8.2% at 13 weeks |
| Sub-Q Phase 3 | Enrolling |
| Oral Phase 3 | Enrolling |
| FDA filing | ~2027 estimated |
Safety profile
Phase 2 GI profile consistent with GLP-1/GIP class. No novel safety signals identified in either formulation. Full tolerability picture pending Phase 3 at longer duration.
Who It's For
- BMI ≥ 30 or ≥ 27 with a weight-related condition
- People who want dual-agonist efficacy (~19–21% range) but prefer or require oral delivery
- Injection-averse patients who've been waiting for an oral option with better efficacy than current choices
Watch Phase 3 results — if the oral formulation confirms Phase 2 efficacy, this becomes the first real dual-agonist pill and the access implications are significant.
Summary(The VK2735 picture)
The dual agonist race's oral candidate. Sub-Q Phase 3 is the near-term bet; the oral Phase 3 is the long-term prize. First dual-agonist pill to reach Phase 3 approval would change the access and cost equation for the entire GLP-1/GIP segment.